Stock Code: Teyi Pharmaceutical Group Co.Ltd(002728) stock abbreviation: Teyi Pharmaceutical Group Co.Ltd(002728) Announcement No.: 2022022
Bond Code: 128025 bond abbreviation: Teyi convertible bond
Teyi Pharmaceutical Group Co.Ltd(002728)
Announcement on the conformity evaluation of the company’s drug magnesium aluminate chewable tablets
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records
Misleading statements or material omissions.
Teyi Pharmaceutical Group Co.Ltd(002728) (hereinafter referred to as “the company”) was recently approved by the State Drug Administration
The notice of approval for supplementary application for drugs of “magnesium aluminate chewable tablets” was approved and issued. After examination, the above drugs were approved
The consistency of quality and efficacy of chemical generic drugs was evaluated. The relevant information of drugs passing the one-time evaluation is as follows:
1、 Main contents of the notice
Drug name dosage form registration specification original drug approval drug registration application content approval conclusion listing license production enterprise classification document number standard number holder
Magnesium aluminate chemical gyzz ybh0463 chemical generic drug passed generic drug Teyi Pharmaceutical Group Co.Ltd(002728) Teyi Pharmaceutical Group Co.Ltd(002728) chewable tablet drug 0.5g h201780052022 quality and efficacy quality and efficacy Group Co., Ltd
2、 Drug related information
Magnesium aluminate chewable tablet is a first-line drug for digestive system. It has the effects of anti acid, anti bile and mucosal protection
Integrated treatment of upper gastrointestinal diseases. The product is suitable for widely treating a variety of stomach diseases: 1 Acute and chronic gastritis;
2. Gastric and duodenal ulcer; 3. Reflux esophagitis; 4. Symptoms of stomach discomfort related to gastric acid, such as stomach pain and heartburn
Heat, acid belching, fullness, etc; 5. Prevent gastric mucosal injury caused by non steroidal drugs. It can be widely used in digestive department and emergency department
Department, otolaryngology, neurology and other departments. Its main medicine magnesium aluminate is a crystalline powder insoluble in water, which is in a layered network
Collateral structure, not absorbed by gastrointestinal tract after oral administration, with high safety.
3、 Impact on the company
The company has the production qualification of integrating magnesium aluminate raw materials and preparations. The company’s passing of the consistency evaluation of magnesium aluminate chewable tablets will benefit the majority of patients and enhance the market competitiveness and influence of the company’s products under the condition of further ensuring the curative effect of the products. In the later stage, the company will actively participate in the bidding for centralized purchase of magnesium aluminate chewable tablets, increase marketing channels and enhance the coordination with its subsidiaries in raw material production.
The passing of consistency evaluation of magnesium aluminate chewable tablets also provides valuable experience for the company’s subsequent varieties to pass the consistency evaluation of generic drug quality and efficacy.
4、 Risk tips
As the drug sales are affected by uncertain factors such as national policies and market environment, the future production and sales of the drug are uncertain. Please make careful decisions and pay attention to preventing investment risks.
It is hereby announced.
Teyi Pharmaceutical Group Co.Ltd(002728) board of directors April 25, 2022
